NCT05718258 - A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

January 29, 2024

Study Completion Date

January 29, 2024

Conditions

Hepatic Function Abnormal

Interventions

DRUG

Venglustat (GZ402671)

"Pharmaceutical form: tablet~Route of administration: oral"

Trial Locations (6)

Investigational Site Number : 2760001, Kiel

Clinical Pharmacology of Miami Site Number : 8400002, Miami

Volunteer Research Group-NOCCR Site Number : 8400003, Knoxville

Nucleus Network Site Number : 8400001, Saint Paul

American Research Corporation Site Number : 8400005, San Antonio

Inland Empire Liver Foundation Site Number : 8400004, Rialto